Thus far, multiple clinical trials in different phases have suggested the efficacy and safety of combining KRAS G12C inhibitors with RTK inhibitors, especially EGFR inhibitors, for advanced KRAS G12C-mutated CRC (20, 27–31). Here, EGFR is linked to colorectal carcinoma.